Whether healthy or diseased, human cells exhibit behaviors and processes that are largely dictated by growth factor molecules, which bind to receptors on the cells. For example, growth factors tell the cells to divide, move, and when to die--a process known as apoptosis. When growth factor ... more
University of Illinois announces new partnership with ZEISS labs@location program
Director of the Carl R. Woese Institute for Genomic Biology Gene Robinson (left) is with President of Carl Zeiss Microscopy LLC James Sharp.
A new agreement between the Carl R. Woese Institute for Genomic Biology (IGB) at the University of Illinois at Urbana-Champaign and ZEISS has named the Core Facilities at IGB as an official ZEISS labs@location Partner. The model facility will allow researchers from around the U.S. to test-drive new instruments in the IGB's Core Facilities Microscopy Suite. This partnership represents the first North American location of the ZEISS labs@location partner program, already in use across Europe.
"With this special partnership with IGB Core Facilities, we transfer a successful labs@location program from Europe to the U.S.," said Jim Sharp, President Carl Zeiss Microscopy LLC. "labs@location is a community of our ZEISS customers and partners providing in depth knowledge and dedicated services. We are very excited that the IGB becomes our first American ZEISS labs@location."
The agreement will allow IGB and Illinois researchers access to select cutting edge technologies immediately following--or in some cases before--their broad release. New instruments, on loan from ZEISS, will cycle through the Core and be available to all users during that time.
In addition, the agreement provides for training and classes taught by ZEISS personnel at the IGB that will better position Core staff and researchers to best utilize new equipment. ZEISS instrument specialists will provide instruction and instrument demos to Illinois and visiting scientists, as well as assist in training the IGB Core staff to provide similar instruction themselves.
"ZEISS training is really valuable," said Core Facilities Director Glenn Fried, "but until now, you've had to send your people to the ZEISS Microscopy Customer Center in New York twice a year to see that benefit. Now all of my staff, as well as graduate students, postdocs, and faculty, can come to those classes at the IGB."
Fried anticipates that one of the first new instruments under the agreement will be a ZEISS Celldiscoverer 7, a new automated microscopy platform for high throughput live cell imaging. Though the IGB has equipment for that purpose, Fried says that the ZEISS Celldiscoverer 7 offers improved clarity and visibility, allowing for sharper and more accurate images.
"This is a really exciting thing for the Core, and for everyone who uses our instruments," said Fried. "Researchers will have access to the newest technology--like ZEISS Celldiscoverer--long before they would if we had to write a grant or even just went out and bought it."
In all, the ZEISS partnership promises to establish itself as a regional center of excellence in biological imaging by attracting researchers from around the country to demo new instruments and attend trainings.
"We are thrilled to partner with ZEISS in this way, because it will enhance the research capabilities of scientists studying many different types of questions, thus enabling the IGB to provide an important new benefit to the campus. Being selected by ZEISS to be the first labs@location in North America is a great honor, and a recognition of the excellence of our Core Facilities and especially the entire Core Facilities staff," said IGB Director Gene Robinson.
- live cell imaging
- Carl Zeiss
A team of researchers from the University of Illinois at Urbana-Champaign and Mayo Clinic have engineered a new type of molecular probe that can measure and count RNA in cells and tissue without organic dyes. The probe is based on the conventional fluorescence in situ hybridization (FISH) t ... more
The rise of genomics, the shift from considering genes singly to collectively, is adding a new dimension to medical care; biomedical researchers hope to use the information contained in human genomes to make better predictions about individual health, including responses to therapeutic drug ... more
At its meeting on 24 September 2019, the Supervisory Board of Carl Zeiss AG unanimously voted in favor of the following changes to the Executive Board: Dr. Karl Lamprecht, currently a Member of the Executive Board, will become the new President & CEO effective 1 April 2020. With this appoin ... more
The ZEISS Group had a successful end to the first six months of fiscal year 2018/19 (ended 31 March 2019) and saw its revenue rise by 9 percent to EUR 3.019 billion (1st six months of 2017/18: EUR 2.773 billion). 90 percent of this sum was generated by markets outside Germany. At EUR 443 mi ... more
Effective 1 October 2018, Dr. Christian Müller will become Chief Financial Officer (CFO) of Carl Zeiss AG. He will succeed Thomas Spitzenpfeil who, as previously announced, will leave the company. Müller has been CFO of the ZEISS subsidiary Carl Zeiss Meditec AG since 2009. He joined the ZE ... more
- 1analytica 2020: The leading guide to the smart laboratory
- 2Sartorius signs agreement to acquire select Danaher Life Science platform businesses
- 3Mini-spectrometer: Smaller than a coin
- 4Obesity risk quantification: a jump towards the future through the lens of artificial intelligence applied to lipid science
- 5CRISPR-edited C. elegans identifies vulnerabilities in cancer
- 6Monitoring the corrosion of bioresorbable magnesium
- 7QIAGEN announces CEO leadership transition
- 8New method identifies aggressive breast cancer
- 9CEM acquires key assets of Intavis Bioanalytical Instruments
- 10Diagnostics for everyone
- Is it time to abandon the Nobel Prize?
- Imperial and Tsinghua University launch seed fund for 'ambitious collaborations'
- Analytik Jena and BAM agree to cooperate in research
- Google provides open source library for quantum chemistry
- Adjustment of drug dose for rheumatoid arthritis by diagnostic method
- Scientists design built-in controls for mini-chemical labs on a chip
- Better biosensor technology created for stem cells
- Scientists crack structure of a novel enzyme linked to cell growth and cancer
- Implantable cancer traps could provide earlier diagnosis
- Scientists work toward a rapid point-of-care diagnostic test for Lyme disease